EASTERN COOPERATIVE ONCOLOGY GROUP

这项建议的主要目标是获得资金，以帮助 支持范德比尔特大学的癌症临床研究。从10月份开始， 1977年至1986年6月，临床研究得到了部分资金的支持 是通过东南癌症研究小组获得的。与 解散SECSG，范德比尔特调查人员寻求并获得 东方合作肿瘤学小组的成员。经社理事会的成员资格 是在融资周期结束时出现的，只有有限的“启动”资金 在这一过渡过程中提供了协助。的具体目标 这一建议包括：1)增加全集团阶段的参与度 II和III期临床试验，2)开发创新疗法 肺癌、睾丸癌、淋巴瘤和其他疾病的治疗方案 恶性肿瘤，3)参与和发展药理学研究 将与正在进行的ECOG试验一起使用，4)在 正在进行的集团范围内的骨髓移植研究和开发 新的研究，5)并保持高质量的数据管理，如 之前在我们与SECSG的长期合作中建立了。这些 目标将通过调查人员的密切合作来实现 来自肿瘤内科和血液科的协助 来自放射肿瘤、外科和医疗部门的调查人员 病理学。范德比尔特的调查人员是几种疾病的成员- 以委员会为导向，主持几项试点和集团范围的研究。我们的 骨髓移植服务获得ECOG批准。我们有一个 优秀的临床药理学课程，历史悠久， 正在积极参加经社理事会的活动。总而言之，范德比尔特 调查人员准备成为ECOG的主要贡献者 患者收益的条款以及创新的发展 治疗方案。

The primary objective of this proposal is to secure funding to help support clinical cancer research at Vanderbilt University. From October, 1977 until June, 1986, clinical research was partly supported by funds obtained through the Southeastern Cancer Study Group. With the disbanding of the SECSG, Vanderbilt investigators sought and obtained membership in the Eastern Cooperative Oncology Group. Membership in ECOG came at the end of a funding cycle and only limited "start-up" funds have been made available to assist in this transition. The specific aims of this proposal include: 1) to increase participation in group-wide phase II and phase III clinical trials, 2) to develop innovative treatment protocols for lung cancer, testicular cancer, lymphomas and other malignancies, 3) participation in and development of pharmacology studies to be used in conjunction with ongoing ECOG trials, 4) collaboration in ongoing group-wide bone marrow transplantation studies and development of new studies, 5) and to maintain the high quality of data management as previously established during our long association with SECSG. These goals will be obtained through the close cooperation of investigators from the divisions of medical oncology and hematology and the assistance of investigators from the departments of radiation oncology, surgery and pathology. Vanderbilt investigators are members of several disease- oriented committees and chair several pilot and group-wide studies. Our bone marrow transplantation service is ECOG approved. We have an outstanding clinical pharmacology program which is well established and is actively participating in ECOG activities. In summary, Vanderbilt investigators are poised to become major contributors to ECOG both in terms of patient accrual as well as the development of innovative treatment protocols.